Porous silicon microarray for simultaneous fluorometric immunoassay of the biomarkers prostate-specific antigen and human glandular kallikrein 2

被引:8
作者
Lee, SangWook [1 ,2 ]
Hosokawa, Kazuo [1 ]
Kim, Soyoun [3 ]
Jeong, Ok Chan [4 ]
Lilja, Hans [5 ,6 ,7 ,8 ,9 ,10 ]
Laurell, Thomas [11 ]
Maeda, Mizuo [1 ]
机构
[1] RIKEN, Bioengn Lab, Wako, Saitama 3510198, Japan
[2] Univ Tokyo, Dept Chem, Tokyo 1130033, Japan
[3] Dongguk Univ, Dept Biomed Engn, Seoul 100715, South Korea
[4] Inje Univ, Dept Mech Engn, Gimhae Si, South Korea
[5] Lund Univ, Skane Univ Hosp Malmo, Dept Translat Med, S-20502 Malmo, Sweden
[6] Mem Sloan Kettering Canc Ctr, Dept Lab Med, New York, NY 10065 USA
[7] Mem Sloan Kettering Canc Ctr, Dept Surg Urol, New York, NY 10065 USA
[8] Mem Sloan Kettering Canc Ctr, Dept Med GU Oncol, New York, NY 10065 USA
[9] Univ Tampere, Inst Biosci & Med Technol, Tampere 33800, Finland
[10] Univ Oxford, Nuffield Dept Surg Sci, Oxford OX3 7DQ, England
[11] Lund Univ, Dept Biomed Engn, S-22100 Lund, Sweden
关键词
Duplex antibody microarray; PSA; hK2; Silicon anodization; Prostate cancer; Serum analysis; RADICAL PROSTATECTOMY; TOTAL PSA; CANCER; SERUM; PROTEIN; ANTIBODY; TECHNOLOGIES; EXPRESSION; PREDICTION; CARCINOMA;
D O I
10.1007/s00604-016-1986-1
中图分类号
O65 [分析化学];
学科分类号
070302 ; 081704 ;
摘要
The authors have developed a porous silicon (P-Si) based duplex antibody microarray platform for simultaneous quantitation of the biomarkers prostate-specific antigen (PSA) and human glandular kallikrein 2 (hK2) in serum. Pore size-controlled P-Si surfaces have an extremely enlarged surface area that enables high-density immobilization of fluorescently labeled antibodies by physical adsorption. Automated microarraying of the antibodies provides a fast and reproducible duplex format of antibody arrays on the P-Si chips placed in the wells of a microtiter plate. The assay platform showed a 100 fg center dot mL(-1) limit of detection for both PSA and hK2, and a dynamic range that extends over five orders of magnitude. After optimization of the density of both capture antibodies, neither the PSA nor the hK2 array showed cross-sensitivity to non-target proteins or other plasma proteins. The microarray was evaluated by titration of PSA and hK2, respectively, in the same serum samples. In our perception, this highly sensitive and selective platform holds promise for improved detection of tumor markers in an early diagnostic stage, but also to monitor the recurrence of prostate cancer.
引用
收藏
页码:3321 / 3327
页数:7
相关论文
共 36 条
  • [21] Global analysis of protein phosphorylation in yeast
    Ptacek, J
    Devgan, G
    Michaud, G
    Zhu, H
    Zhu, XW
    Fasolo, J
    Guo, H
    Jona, G
    Breitkreutz, A
    Sopko, R
    McCartney, RR
    Schmidt, MC
    Rachidi, N
    Lee, SJ
    Mah, AS
    Meng, L
    Stark, MJR
    Stern, DF
    De Virgilio, C
    Tyers, M
    Andrews, B
    Gerstein, M
    Schweitzer, B
    Predki, PF
    Snyder, M
    [J]. NATURE, 2005, 438 (7068) : 679 - 684
  • [22] Recker F, 1998, CANCER, V83, P2540, DOI 10.1002/(SICI)1097-0142(19981215)83:12<2540::AID-CNCR20>3.0.CO
  • [23] 2-V
  • [24] Macro-/nanoporous silicon as a support for high-performance protein microarrays
    Ressine, A
    Ekström, S
    Marko-Varga, G
    Laurell, T
    [J]. ANALYTICAL CHEMISTRY, 2003, 75 (24) : 6968 - 6974
  • [25] Use of prostate-specific antigen (PSA) isoforms for the detection of prostate cancer in men with a PSA level of 2-10 ng/ml: Systematic review and meta-analysis
    Roddam, AW
    Duffy, MJ
    Hamdy, FC
    Ward, AM
    Patnick, J
    Price, CP
    Rimmer, J
    Sturgeon, C
    White, P
    Allen, NE
    [J]. EUROPEAN UROLOGY, 2005, 48 (03) : 386 - 399
  • [26] Serum human glandular kallikrein 2 (hK2) for distinguishing stage and grade of prostate cancer
    Stephan, C
    Jung, K
    Nakamura, T
    Yousef, GM
    Kristiansen, G
    Diamandis, EP
    [J]. INTERNATIONAL JOURNAL OF UROLOGY, 2006, 13 (03) : 238 - 243
  • [27] Comparison of free and total forms of serum human kallikrein 2 and prostate-specific antigen for prediction of locally advanced and recurrent prostate cancer
    Steuber, Thomas
    Vickers, Andrew J.
    Serio, Angel M.
    Vaisanen, Ville
    Haese, Alexander
    Pettersson, Kim
    Eastham, James A.
    Scardino, Peter T.
    Huland, Hartwig
    Lilja, Hans
    [J]. CLINICAL CHEMISTRY, 2007, 53 (02) : 233 - 240
  • [28] Sandwich immunoassay for the prostate specific antigen using a micro-fluxgate and magnetic bead labels
    Sun, Xue-cheng
    Lei, Chong
    Guo, Lei
    Zhou, Yong
    [J]. MICROCHIMICA ACTA, 2016, 183 (08) : 2385 - 2393
  • [29] Long-term survival probability in men with clinically localized prostate cancer treated either conservatively or with definitive treatment (radiotherapy or radical prostatectomy)
    Tewari, Ashutosh
    Raman, Jay D.
    Chang, Peter
    Rao, Sandhya
    Divine, George
    Menon, Mani
    [J]. UROLOGY, 2006, 68 (06) : 1268 - 1274
  • [30] Nanoparticle-based bio-barcode assay redefines "undetectable'' PSA and biochemical recurrence after radical prostatectomy
    Thaxton, C. Shad
    Elghanian, Robert
    Thomas, Audrey D.
    Stoeva, Savka I.
    Lee, Jae-Seung
    Smith, Norm D.
    Schaeffer, Anthony J.
    Klocker, Helmut
    Horninger, Wolfgang
    Bartsch, Georg
    Mirkin, Chad A.
    [J]. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 2009, 106 (44) : 18437 - 18442